Payment overview · 2025
General Payments
$1,323.46
13 reported records · 8 companies
Healthcare provider profile · identity verified
Bhavin C Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · BRADENTON, FL · NPI 1619234416
Verified facts
What the public records show
CMS Open Payments records show Bhavin C Patel, MD received $1,323.46 in general payments during 2025 across 13 reported records.
Kerecis Limited accounted for 84.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Velphoro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kerecis Limited | Unresolved — no canonical attribution shown | $1,115.98 | 84.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.02 | 4.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $33.77 | 2.5% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $29.26 | 2.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.87 | 2.2% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $24.51 | 1.9% | 1 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $21.17 | 1.6% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.88 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $773.09 | 12 |
| Travel and Lodging | $550.37 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $1,115.98 | 5 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $1,115.98 | 5 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $33.77 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.52 | 1 | 2025 |
Source payment records
|
|||||
| INTHRILL THROMBECTOMY CATHETER Normalized: inthrill thrombectomy catheter |
Device | Stryker Corporation | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| 2008T BlueStar Hemodialysis Machine Normalized: 2008t bluestar hemodialysis machine |
Device | Fresenius USA Marketing, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| CRIT-LINE Normalized: crit line |
Device | Fresenius USA Marketing, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| OPTIFLUX Normalized: optiflux |
Device | Fresenius USA Marketing, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 120 | 47 |
| Lisinopril | Lisinopril | 109 | 39 |
| Nifedipine Er | Nifedipine | 106 | 36 |
| Bumetanide | Bumetanide | 56 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 22 |
| Losartan Potassium | Losartan Potassium | 39 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 37 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 17 |
| Carvedilol | Carvedilol | 31 | 11 |
| Potassium Chloride | Potassium Chloride | 28 | 15 |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Tacrolimus | Tacrolimus | 15 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,323.46 · 13 records | Kerecis Limited | 2008T BlueStar Hemodialysis Machine, CRIT-LINE, Empaveli, Fabhalta, INTHRILL THROMBECTOMY CATHETER, Kerecis GraftGuide, Kerecis SurgiClose, LUPKYNIS, NUCALA, OPTIFLUX, QULIPTA, TRELEGY ELLIPTA, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Fresenius USA Marketing, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error